Geraldine Honnet
Chief Medical Officer at Sensorion | Greater Paris Metropolitan Region, France
Geraldine Honnet’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
ContactOut Insights • AI Generated
Geraldine Honnet serves as Chief Medical Officer at Sensorion, a clinical-stage biotechnology company developing novel therapies for hearing loss disorders headquartered in the Greater Paris Metropolitan Region. She leads medical and clinical strategy for the firm’s portfolio, most notably overseeing the Phase 2 proof of concept study of SENS-401 for cisplatin-induced ototoxicity and cochlear implantation patients. Her career is grounded in training from Université Necker-Enfants Malades, equipping her to manage cross-institutional partnerships and therapeutic development initiatives.
BEST APPROACH TO REACH Geraldine Honnet
Leveraging the strong work-data confidence, initiate contact through a targeted LinkedIn connection request accompanied by a direct work email that references Sensorion’s Phase 2 Arazasetron development pipeline to streamline professional networking.
Chief Medical Officer at Sensorion in February 2020 - Present
Director Of Development at Genethon in July 2017 - January 2020
Director of Clinical Development at Genethon in May 2011 - July 2017
Senior Clinical Project Manager at Transgene in October 2007 - April 2011
European Project Manager Virology at Janssen-Cilag EMEA in October 2005 - October 2007
Medical Director at Parexel International in June 2001 - September 2005
Université Necker-Enfants Malades, MD, July 1994 to July 1996
University of Paris I: Panthéon-Sorbonne, DEA, July 2026
Université Lariboisière, MSc, July 1999 to July 2026
Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with the Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).
Discover more about Sensorion
Ressources Humaines
HR Business Partner at Sensorion
(Apr 2021 – Present)
Chief Operation Officer, Corporate Strategy , Product Development, Regulatory Strategy
Advisor, Start Up, Market Development, Strategy, Communication & Public Affairs at Sensorion
(Nov 2023 – Present)
Head of Investor Relations and Communication
Head of Investor Relations and Communication at Sensorion
(Sep 2025 – Present)
CFO at Sensorion
Chief Financial Officer at Sensorion
(Jun 2024 – Present)
Head of Preclinical Development at Sensorion
Sensorion is a biopharmaceutical company developing life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss (gene therapy, small molecules).
PhD Biomedical - Scientist III - Gene Therapy (In vivo - In vitro)
Scientist II - Gene therapy at Sensorion
(Apr 2021 – Present)
What is Geraldine Honnet email address?
Email Geraldine Honnet at [email protected] and [email protected]. This email is the most updated Geraldine Honnet's email found in 2026.
How to contact Geraldine Honnet?
To contact Geraldine Honnet send an email to [email protected] or [email protected]. (updated on November 13, 2025)
What company does Geraldine Honnet work for?
Geraldine Honnet works for Sensorion.
What is Geraldine Honnet's role at Sensorion?
Geraldine Honnet is Chief Medical Officer
What industry does Geraldine Honnet work in?
Geraldine Honnet works in the Biotechnology industry.
